Do DIO1 variants limit free T4 to free T3 conversion without raising reverse T3?

Genetic variations in the iodothyronine deiodinase 1 (DIO1) gene play a key role in dictating peripheral thyroid hormone metabolism and the conversion of thyroid precursors to their active forms.

Clinical and genetic evidence

• Genetic variants and DIO1 activity: Genome-wide association studies (GWAS) and cohort analyses demonstrate that common single nucleotide polymorphisms (such as rs2235544 and rs11206244) directly alter type 1 deiodinase (DIO1) enzyme activity in vivo.
• Impaired T4 to T3 conversion: Because DIO1 catalyzes the outer-ring deiodination of thyroid hormones, genetically reduced enzyme activity limits the peripheral conversion of free T4 (FT4) into active free T3 (FT3), resulting in a clinically observable reduction in the FT3/FT4 ratio.

Mechanistic explanations

• Reverse T3 clearance dynamics: DIO1 serves as the primary clearing enzyme for circulating reverse T3 (rT3) via inner-ring deiodination. rT3 is the preferred metabolic substrate for the DIO1 enzyme.
• Inevitable rT3 accumulation: Because of this substrate preference, any genetic variation that impairs DIO1-mediated T4-to-T3 conversion concurrently compromises the clearance of rT3. Consequently, a peripheral limitation in T3 production via this pathway is mechanistically tied to, and accompanied by, elevated serum rT3 levels.

Bottom line

• Common DIO1 genetic variants directly impair the conversion of free T4 to active free T3. However, because the DIO1 enzyme is the primary pathway for clearing reverse T3, this impairment is mechanistically linked to decreased rT3 clearance and subsequent elevated serum rT3, refuting the claim of an rT3-independent conversion limitation.